title: [Etanercept on steroid-refractary acute graft-versus-host disease].
abstract: Objetive: To describe etanercept use and effectiveness on steroid- refractary acute graft-versus-host disease after hematopoietic cell transplantation.
  
  
  METHODS
  Patients treated with etanercept as off label use for steroid-refractary acute graft-versus-host disease were selected and each patient's medical history was reviewed to assess the clinical response.
  
  
  RESULTS
  The study included five patients: four presented with digestive manifestations and one presented pulmonary and liver manifestations. 80% of patients showed a clinical response: 60% a partial response and 20% a total response. In four cases etanercept 25mg was administered twice a week with variable duration of treatment, achieving no response in 1 case (3 weeks), partial response in two 2 cases (4 weeks and 8 weeks) and a complete response in 1 case (8 week period). Only one case was treated with etanercept 50mg administered twice a week for 5 weeks with a partial treatment response.
  
  
  CONCLUSIONS
  The clinical response rate is consistent with the previously published data. This updates the scarce bibliographic information about etanecept use in steroid-refractary acute graft-versus-host disease. Due to clinical design limitations and the small patient population, future clinical studies should be conducted to assess the efficacy and security of etanercept in these patients.
authors.affiliation: Servicio de Farmacia Hospitalaria. Hospital Universitario de Gran Canaria Doctor Negrín. España.. silviaglezmunguia@hotmail.com.
authors.forename: Silvia
authors.initials: S
authors.lastname: González Munguía
authors.affiliation: Servicio de Farmacia Hospitalaria. Hospital Universitario de Gran Canaria Doctor Negrín. España.. silviaglezmunguia@hotmail.com.
authors.forename: Moisés
authors.initials: M
authors.lastname: Pérez León
authors.affiliation: Servicio de Farmacia Hospitalaria. Hospital Universitario de Gran Canaria Doctor Negrín. España.. silviaglezmunguia@hotmail.com.
authors.forename: Marta
authors.initials: M
authors.lastname: Piñero González
authors.affiliation: Servicio de Farmacia Hospitalaria. Hospital Universitario de Gran Canaria Doctor Negrín. España.. silviaglezmunguia@hotmail.com.
authors.forename: Marina Magnolia
authors.initials: MM
authors.lastname: Díaz Pestano
authors.affiliation: Servicio de Farmacia Hospitalaria. Hospital Universitario de Gran Canaria Doctor Negrín. España.. silviaglezmunguia@hotmail.com.
authors.forename: Rafael
authors.initials: R
authors.lastname: Molero Gómez
authors.affiliation: Servicio de Hematología y Hemoterapia. Hospital Universitario de Gran Canaria Doctor Negrín. España.. silviaglezmunguia@hotmail.com.
authors.forename: Hugo Daniel
authors.initials: HD
authors.lastname: Luzardo Henríquez
mesh_terms: D000328:Adult; D000368:Aged; D004351:Drug Resistance; D000068800:Etanercept / Q000627:therapeutic use*; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013256:Steroids / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D013256:Steroids; D000068800:Etanercept